Top

Published in:

Open Access 01-04-2019 | Parkinson's Disease | Neurology and Preclinical Neurological Studies - Original Article

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment

Authors: Dasiel O. Borroto-Escuela, Kjell Fuxe

Published in: Journal of Neural Transmission | Issue 4/2019

Abstract

The adenosine homo, iso and heteroreceptor complexes in the basal ganglia play a highly significant role in modulating the indirect and direct pathways and the striosomal projections to the nigro-striatal DA system. The major adenosine receptor complexes in the striato-pallidal GABA neurons can be the A2AR–D2R and A2AR–D2R–mGluR5 receptor complexes, in which A2AR protomers and mGluR5 protomers can allosterically interact to inhibit D2R protomer signaling. Through a reorganization of these heteroreceptor complexes upon chronic dopaminergic treatment a pathological and prolonged inhibition of D2R receptor protomer signaling can develop with motor inhibition and wearing off of the therapeutic effects of levodopa and dopamine receptor agonists. The direct pathway is enriched in D1R in and around glutamate synapses enhancing the ability of these GABA neurons to be activated and increase motor initiation. The brake on these GABA neurons is in this case exerted by A1R forming A1R–D1R heteroreceptor complexes in which they allosterically inhibit D1R signaling and thereby reduce motor initiation. Upon chronic levodopa treatment a reorganization of the D1R heteroreceptor complexes develops with the formation of putative A1R–D1R–D3 in addition to D1R–D3R complexes in which D3R enhances D1R protomer signaling and may make the A1R protomer brake less effective. Alpha-synuclein monomers–dimers are postulated to form complexes with A2AR homo and heteroprotomers in the plasma membrane enhancing alpha-synuclein aggregation and toxicity. The alpha-synuclein fibrils formed in the A2AR enriched dendritic spines of the striato-pallidal GABA neurons may reach the surrounding DA terminals via extracellular-vesicle-mediated volume transmission involving internalization of the vesicles and their cargo (alpha-synuclein fibrils) into the vulnerable DA terminals, enhancing their degeneration followed by retrograde flow of these fibrils in the DA axons to the vulnerable nigral DA nerve cells.

Agnati LF, Fuxe K (2014) Extracellular-vesicle type of volume transmission and tunnelling-nanotube type of wiring transmission add a new dimension to brain neuro-glial networks Philosophical transactions of the Royal Society of London Series B Biol Sci https://doi.org/10.1098/rstb.2013.0505 CrossRef

Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K (1964) Demonstration and mapping out of nigro-neoestriatal dopamine neurons. Life Sci 3:523–530CrossRef

Antonelli T, Fuxe K, Agnati L, Mazzoni E, Tanganelli S, Tomasini MC, Ferraro L (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson’s disease. relevance for L-dopa induced dyskinesias. J Neurol Sci 248:16–22. https://doi.org/10.1016/j.jns.2006.05.019 CrossRefPubMed

Audet N, Galés C, Archer-Lahlou E, Vallières M, Schiller PW, Bouvier M, Pineyro G (2008) Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem 283:15078–15088CrossRefPubMedPubMedCentral

Azdad K, Gall D, Woods AS, Ledent C, Ferre S, Schiffmann SN (2009) Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization Neuropsychopharmacology: official publication of the American College. Neuropsychopharmacology 34:972–986. https://doi.org/10.1038/npp.2008.144 CrossRefPubMed

Beggiato S et al (2016) Functional role of striatal A2A, D2, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission. J Neurochem 138:254–264. https://doi.org/10.1111/jnc.13652 CrossRefPubMed

Besancon E, Guo S, Lok J, Tymianski M, Lo EH (2008) Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 29:268–275. https://doi.org/10.1016/j.tips.2008.02.003 CrossRefPubMed

Bezard E (2003) Neuroprotection for Parkinson’s disease: a call for clinically driven experimental design. Lancet Neurol 2:393CrossRefPubMed

Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–9CrossRefPubMed

Borroto-Escuela DO, Fuxe K (2017) Diversity and bias through dopamine D2R heteroreceptor complexes. Curr Opin Pharmacol 32:16–22. https://doi.org/10.1016/j.coph.2016.10.004 CrossRefPubMed

Borroto-Escuela DO et al (2010a) A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R. Biochem Biophys Res Commun 394:222–227 https://doi.org/10.1016/j.bbrc.2010.02.168 CrossRefPubMed

Borroto-Escuela DO et al (2010b) Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem Biophys Res Commun 393:767–772. https://doi.org/10.1016/j.bbrc.2010.02.078 CrossRefPubMed

Borroto-Escuela DO et al (2010c) Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem Biophys Res Commun 402:801–807. https://doi.org/10.1016/j.bbrc.2010.10.122 CrossRefPubMed

Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Ciruela F, Agnati LF, Fuxe K (2011) On the existence of a possible A2A-D2-beta-Arrestin2 complex: A2A agonist modulation of D2 agonist-induced beta-arrestin2 recruitment. J Mol Biol 406:687–699. https://doi.org/10.1016/j.jmb.2011.01.022 CrossRefPubMed

Borroto-Escuela DO et al (2012) Fibroblast growth factor receptor 1- 5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol Psychiatry 71:84–91. https://doi.org/10.1016/j.biopsych.2011.09.012 CrossRefPubMed

Borroto-Escuela DO, Corrales F, Narvaez M, Oflijan J, Agnati LF, Palkovits M, Fuxe K (2013a) Dynamic modulation of FGFR1-5-HT1A heteroreceptor complexes. Agonist treatment enhances participation of FGFR1 and 5-HT1A homodimers and recruitment of beta-arrestin2. Biochem Biophys Res Commun 441:387–392 https://doi.org/10.1016/j.bbrc.2013.10.067 CrossRefPubMed

Borroto-Escuela DO, Flajolet M, Agnati LF, Greengard P, Fuxe K (2013b) Bioluminescence resonance energy transfer methods to study G protein-coupled receptor–receptor tyrosine kinase heteroreceptor complexes. Methods Cell Biol 117:141–164. https://doi.org/10.1016/B978-0-12-408143-7.00008-6 CrossRefPubMedPubMedCentral

Borroto-Escuela DO et al (2013c) G protein-coupled receptor heterodimerization in the brain. Methods Enzymol 521:281–294. https://doi.org/10.1016/B978-0-12-391862-8.00015-6 CrossRefPubMed

Borroto-Escuela DO et al (2014a) The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int J Mol Sci 15:8570–8590. https://doi.org/10.3390/ijms15058570 CrossRefPubMedPubMedCentral

Borroto-Escuela DO et al (2014b) Preferential activation by galanin 1–15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex. Biochem Biophys Res Commun 452:347–353. https://doi.org/10.1016/j.bbrc.2014.08.061 CrossRefPubMed

Borroto-Escuela DO, Agnati LF, Bechter K, Jansson A, Tarakanov AO, Fuxe K (2015a) The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural-glial networks Philosophical transactions of the Royal Society of London Series B. Biol Sci https://doi.org/10.1098/rstb.2014.0183 CrossRef

Borroto-Escuela DO et al (2015b) On the role of the balance of GPCR Homo/heteroreceptor complexes in the brain. J Adv Neurosci Res 2:36–44CrossRef

Borroto-Escuela DO et al (2016) In situ proximity ligation assay to study and understand the distribution and balance of GPCR homo- and heteroreceptor complexes in the brain. In: Lujan R, Ciruela F (eds) Receptor and ion channel detection in the brain. Springer, Berlin, pp 109–126. https://doi.org/10.1515/revneuro-2015-0024 CrossRef

Borroto-Escuela DO et al (2017a) Understanding the role of GPCR heteroreceptor complexes in modulating the brain networks in health and disease frontiers in cellular. Neuroscience 11:37 https://doi.org/10.3389/fncel.2017.00037 CrossRef

Borroto-Escuela DO et al (2017b) Cocaine self-administration specifically increases A2AR-D2R and D2R-sigma1R heteroreceptor complexes in the rat nucleus accumbens shell. Relevance for cocaine use disorder pharmacology. Biochem Behav 155:24–31. https://doi.org/10.1016/j.pbb.2017.03.003 CrossRef

Borroto-Escuela DO, Hinz S, Navarro G, Franco R, Muller CE, Fuxe K (2018a) Understanding the role of adenosine A2AR heteroreceptor complexes in neurodegeneration and neuroinflammation frontiers. Neuroscience 12:43 https://doi.org/10.3389/fnins.2018.00043 CrossRef

Borroto-Escuela DO et al (2018b) Mapping the interface of a GPCR dimer: a structural model of the A2A adenosine and D2 dopamine receptor heteromer. Front Pharmacol 9:829. https://doi.org/10.3389/fphar.2018.00829 CrossRefPubMedPubMedCentral

Borroto-Escuela DO, Tarakanov AO, Brito I, Fuxe K (2018c) Glutamate heteroreceptor complexes in the brain. Pharmacol Rep 70:936–950. https://doi.org/10.1016/j.pharep.2018.04.002 CrossRefPubMed

Borroto-Escuela DO, Wydra K, Filip M, Fuxe K (2018d) A2AR-D2R heteroreceptor complexes in cocaine reward and addiction trends in pharmacological sciences 39:1008–1020 https://doi.org/10.1016/j.tips.2018.10.007

Borroto-Escuela DO et al (2018e) Disruption of A2AR-D2R heteroreceptor complexes after A2AR transmembrane 5 peptide administration enhances cocaine self-administration. Rats Mol Neurobiol 55:7038–7048. https://doi.org/10.1007/s12035-018-0887-1 CrossRefPubMed

Borroto-Escuela DO et al (2018f) Disruption of A2AR-D2R heteroreceptor complexes after A2AR transmembrane 5 peptide administration Enhances Cocaine Self-Administration. Rats Mol Neurobiol https://doi.org/10.1007/s12035-018-0887-1 CrossRefPubMed

Brigham E et al (2018) Pharmacokinetic/pharmacodynamic correlation analysis of amantadine for levodopa-induced Dyskinesia. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.118.247650 CrossRefPubMed

Cabello N et al (2009) Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 109:1497–1507. https://doi.org/10.1111/j.1471-4159.2009.06078.x CrossRefPubMedPubMedCentral

Calon F, Di Paolo T (2002) Levodopa response motor complications–GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 8:449–454CrossRefPubMed

Canals M et al (2003) Adenosine A2A-dopamine D2 receptor–receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278:46741–46749. https://doi.org/10.1074/jbc.M306451200 CrossRefPubMed

Canals M et al (2004) Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 88:726–734CrossRefPubMed

Ciruela F et al (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26:2080–2087. https://doi.org/10.1523/JNEUROSCI.3574-05.2006 CrossRefPubMedPubMedCentral

Cristovao-Ferreira S et al (2011) Modulation of GABA transport by adenosine A1R-A2AR heteromers, which are coupled to both Gs- and G(i/o)-proteins. J Neurosci 31:15629–15639. https://doi.org/10.1523/JNEUROSCI.2526-11.2011 CrossRefPubMedPubMedCentral

Cristovao-Ferreira S et al (2013) A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Puriner Signall 9:433–449. https://doi.org/10.1007/s11302-013-9364-5 CrossRef

Crittenden JR, Graybiel AM (2011) Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat 5:59. https://doi.org/10.3389/fnana.2011.00059 CrossRefPubMedPubMedCentral

Crittenden JR et al (2016) Striosome-dendron bouquets highlight a unique striatonigral circuit targeting dopamine-containing neurons. Proc Natl Acad Sci USA 113:11318–11323. https://doi.org/10.1073/pnas.1613337113 CrossRefPubMed

Dahlstroem A, Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. SUPPL 232:231–255

Decressac M, Bjorklund A (2013) TFEB: Pathogenic role and therapeutic target in Parkinson disease. Autophagy 9:1244–1246. https://doi.org/10.4161/auto.25044 CrossRefPubMedPubMedCentral

Diogenes MJ et al (2012) Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 32:11750–11762. https://doi.org/10.1523/JNEUROSCI.0234-12.2012 CrossRefPubMed

Ekstrand MI et al (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Nat Acad Sci USA 104:1325–1330. https://doi.org/10.1073/pnas.0605208103 CrossRefPubMed

Farre D et al (2015) Stronger dopamine D1 receptor-mediated neurotransmission in Dyskinesia. Mol Neurobiol 52:1408–1420. https://doi.org/10.1007/s12035-014-8936-x CrossRefPubMed

Feltmann K et al (2018) Effects of long-term alcohol drinking on the dopamine D2 Receptor: gene expression and heteroreceptor complexes in the striatum in rats alcoholism. Clin Exp Res 42:338–351. https://doi.org/10.1111/acer.13568 CrossRef

Ferraro L, Beggiato S, Tomasini MC, Fuxe K, Antonelli T, Tanganelli S (2012) A(2A)/D(2) receptor heteromerization in a model of Parkinson’s disease focus on striatal aminoacidergic signaling. Brain Res 1476:96–107. https://doi.org/10.1016/j.brainres.2012.01.032 CrossRefPubMed

Ferre S, Fuxe K (1992) Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 594:124–130CrossRefPubMed

Ferre S, Popoli P, Gimenez-Llort L, Finnman UB, Martinez E, Scotti de Carolis A, Fuxe K (1994) Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. Neuroreport 6:73–76CrossRefPubMed

Ferre S et al (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940–11945. https://doi.org/10.1073/pnas.172393799 CrossRefPubMed

Ferreira DG et al (2017) Adenosine A2A Receptors Modulate alpha-Synuclein Aggregation. Toxicity Cerebral Cortex 27:718–730. https://doi.org/10.1093/cercor/bhv268 CrossRefPubMed

Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59–69. https://doi.org/10.1124/mol.107.043885 CrossRefPubMed

Flajolet M et al (2008) FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat Neurosci 11:1402–1409. https://doi.org/10.1038/nn.2216 CrossRefPubMedPubMedCentral

Franco R (2009) Neurotransmitter receptor heteromers in neurodegenerative diseases and neural plasticity. J Neural Trans 116:983–987. https://doi.org/10.1007/s00702-008-0148-y CrossRef

Franco R et al (2007) Receptor–receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Trans 114:93–104. https://doi.org/10.1007/s00702-006-0566-7 CrossRef

Franco R et al (2014) Allosteric communication between Gi and Gs in the A1-A2A receptor tetrameric complex. Puriner Signal 10:738

Franco R, Martinez-Pinilla E, Lanciego JL, Navarro G (2016) Basic pharmacological and structural evidence for class A G-protein-coupled receptor Heteromerization. Front Pharmacol 7:76 https://doi.org/10.3389/fphar.2016.00076 CrossRefPubMedPubMedCentral

Fredholm BB (1995) Purinoceptors in the nervous system. Pharmacol Toxicol 76:228–239CrossRefPubMed

Fredholm BB, Altiok N (1994) Adenosine A2B receptor signalling is altered by stimulation of bradykinin or interleukin receptors in astroglioma cells. Neurochem Int 25:99–102CrossRefPubMed

Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 63:1–34. https://doi.org/10.1124/pr.110.003285 CrossRefPubMedPubMedCentral

Fujiyama F, Sohn J, Nakano T, Furuta T, Nakamura KC, Matsuda W, Kaneko T (2011) Exclusive and common targets of neostriatofugal projections of rat striosome neurons: a single neuron-tracing study using a viral vector The European. J Neurosci 33:668–677. https://doi.org/10.1111/j.1460-9568.2010.07564.x CrossRef

Fuxe K (1965) Evidence for the existence of monoamine neurons in the central nervous system. Iv. Distribution of monoamine nerve terminals in the central nervous system acta physiologica scandinavica supplementum. SUPPL 247:237

Fuxe K, Borroto-Escuela DO (2016) Heteroreceptor complexes and their allosteric receptor–receptor interactions as a novel biological principle for integration of communication in the CNS: targets for drug development neuropsychopharmacology: official publication of the American College. Neuropsychopharmacology 41:380–382. https://doi.org/10.1038/npp.2015.244 CrossRefPubMed

Fuxe K, Fredholm BB, Agnati LF, Corrodi H (1978) Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors. Brain Res 146:295–311CrossRefPubMed

Fuxe K, Agnati LF, Benfenati F, Celani M, Zini I, Zoli M, Mutt V (1983) Evidence for the existence of receptor–receptor interactions in the central nervous system studies on the regulation of monoamine receptors by neuropeptides. J Neural Trans Suppl 18:165–179

Fuxe K et al (1992) Neuropeptides, excitatory amino acid and adenosine A2 receptors regulate D2 receptors via intramembrane receptor–receptor interactions. Relevance for Parkinson’s disease and schizophrenia. Neurochemistry 20:215S–224S

Fuxe K, Ferre S, Snaprud P, von Euler G, Johansson B, Fredholm B (1993) Antagonistic A2A/D2 receptor interactions in the striatum as a basis for adenosine - dopamine interactions for the central nervous system. Drug Dev Res 28:374–380CrossRef

Fuxe K, Ferre S, Zoli M, Agnati LF (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia Brain research. Brain Res Rev 26:258–273CrossRefPubMed

Fuxe K et al (2001) Adenosine receptors and Parkinson’s disease relevance of antagonistic adenosine dopamine receptor interactions in the striatum. Adv Neurol 86:345–353PubMed

Fuxe K et al (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 61:S19–S23CrossRefPubMed

Fuxe K et al (2005) Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci 26:209–220. https://doi.org/10.1385/JMN:26:2-3:209 CrossRefPubMed

Fuxe K et al (2007a) Intramembrane receptor–receptor interactions: a novel principle in molecular medicine. J Neural Trans 114:49–75. https://doi.org/10.1007/s00702-006-0589-0 CrossRef

Fuxe K, Ferre S, Genedani S, Franco R, Agnati LF (2007b) Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 92:210–217. https://doi.org/10.1016/j.physbeh.2007.05.034 CrossRefPubMed

Fuxe K, Marcellino D, Genedani S, Agnati L (2007c) Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson’s disease Movement disorders. J Mov Disorder Soc 22:1990–2017. https://doi.org/10.1002/mds.21440 CrossRef

Fuxe K, Agnati LF, Mora F (2008a) The basal ganglia-from neuronal systems to molecular networks preface. Brain Res Rev 58:247–248CrossRefPubMed

Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati LF (2008b) Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. Physiology (Bethesda) 23:322–332. https://doi.org/10.1152/physiol.00028.2008 CrossRef

Fuxe KG, Tarakanov AO, Goncharova LB, Agnati LF (2008c) A new road to neuroinflammation in Parkinson’s disease? Brain Res Rev 58:453–458. https://doi.org/10.1016/j.brainresrev.2008.04.003 CrossRefPubMed

Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati L (2009a) Brain receptor mosaics and their intramembrane receptor–receptor interactions: molecular integration in transmission and novel targets for drug development. J Acupunct Merid Stud 2:1–25. https://doi.org/10.1016/S2005-2901(09)60011-X CrossRef

Fuxe K, Marcellino D, Leo G, Agnati LF (2009b) Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr Opin Pharmacol 10:14–22. https://doi.org/10.1016/j.coph.2009.10.010 CrossRefPubMed

Fuxe K et al (2010a) The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog Neurobiol 90:82–100. https://doi.org/10.1016/j.pneurobio.2009.10.012 CrossRefPubMed

Fuxe K et al (2010b) Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders CNS. Neurosci Ther 16:e18-42 https://doi.org/10.1111/j.1755-5949.2009.00126.x CrossRef

Fuxe K, Borroto-Escuela D, Fisone G, Agnati LF, Tanganelli S (2014a) Understanding the role of heteroreceptor complexes in the central nervous system Current protein and peptide. Science 15:647

Fuxe K, Borroto-Escuela DO, Ciruela F, Guidolin D, Agnati LF (2014b) Receptor–receptor interactions in heteroreceptor complexes: a new principle in biology focus on their role in learning memory. Neurosci Discov. https://doi.org/10.7243/2052-6946-2-6 CrossRef

Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Palkovits M, Tarakanov AO, Ciruela F, Agnati LF (2014c) Moonlighting proteins and protein–protein interactions as neurotherapeutic targets in the G protein-coupled receptor field Neuropsychopharmacology: official publication of the American College. Neuropsychopharmacology 39:131–155. https://doi.org/10.1038/npp.2013.242 CrossRefPubMed

Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2014d) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Target:1–22 https://doi.org/10.1517/14728222.2014.981529

Fuxe K et al (2014e) Diversity and Bias through receptor–receptor interactions in GPCR heteroreceptor complexes. Focus on examples from dopamine D2 receptor heteromerization. Front Endocrinol 5:71 https://doi.org/10.3389/fendo.2014.00071 CrossRef

Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Target 19:377–398. https://doi.org/10.1517/14728222.2014.981529 CrossRef

Fuxe K, Borroto-Escuela DO, vol Protocols S (2018) Receptor–receptor interactions in the central nervous system. Humana Press, New York. https://doi.org/10.1007/978-1-4939-8576-0 CrossRef

Galter D et al (2010) MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson’s disease Genes. Brain Behav 9:173–181. https://doi.org/10.1111/j.1601-183X.2009.00542.x CrossRef

Gines S et al (2000) Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Nat Acad Sci USA 97:8606–8611. https://doi.org/10.1073/pnas.150241097 CrossRefPubMed

Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA (2011) Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 1808:1380–1399. https://doi.org/10.1016/j.bbamem.2010.12.001 CrossRefPubMed

Graybiel AM, Ragsdale CW (1978) Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci USA 75:5723–5726CrossRefPubMed

Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, Filizola M, Javitch JA (2008) Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 27:2293–2304. https://doi.org/10.1038/emboj.2008.153 CrossRefPubMedPubMedCentral

Hauser RA (2011) Future treatments for Parkinson’s disease: surfing the PD pipeline the international. J Neurosci 2:53–62. https://doi.org/10.3109/00207454.2011.620195 CrossRef

Hillion J et al (2002) Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277:18091–18097. https://doi.org/10.1074/jbc.M107731200 CrossRefPubMed

Hinz S et al (2017) Adenosine A2B receptors block A2A receptor signaling. In: Meeting PC (ed) 7th Joint Italian-German Purine Club Meeting “Advances in basic and translational purinergic research”, vol 1. Sapienza University, Rome

Hinz S et al (2018) Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors. Oncotarget 9:13593–13611. https://doi.org/10.18632/oncotarget.24423 CrossRefPubMedPubMedCentral

Hu Q et al (2016) Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy. Exp Neurol 283:213–223. https://doi.org/10.1016/j.expneurol.2016.05.040 CrossRefPubMed

Jaberi E et al (2016) Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction movement disorders. J Mov Disorder Soc 31:1004–1011. https://doi.org/10.1002/mds.26627 CrossRef

Kostrzewa RM et al (2018) Dopamine D2 receptor supersensitivity as a spectrum of neurotoxicity and status in psychiatric disorders. J Pharmacol Exp Ther 366:519–526. https://doi.org/10.1124/jpet.118.247981 CrossRefPubMed

Laurent C et al (2016) A2A adenosine receptor deletion is protective in a mouse model of. Tauopathy Mol Psychiatry 21:97–107. https://doi.org/10.1038/mp.2014.151 CrossRefPubMed

Lee FJ, Liu F (2004) Direct interactions between NMDA and D1 receptors: a table of tails. Biochem Soc Trans 32:1032–1036CrossRefPubMed

Lee FJ et al (2002) Dual regulation of NMDA receptor functions by direct protein–protein interactions with the dopamine D1 receptor. Cell 111:219–230CrossRefPubMed

Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB (2000) Direct protein–protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid. A Receptors Nat 403:274–280. https://doi.org/10.1038/35002014 CrossRef

Liu XY et al (2006) Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52:897–909. https://doi.org/10.1016/j.neuron.2006.10.011 CrossRefPubMed

Loschmann PA et al (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson’s disease. Exp Neurol 187:86–93. https://doi.org/10.1016/j.expneurol.2004.01.018 CrossRefPubMed

Luquin MR, Laguna J, Obeso JA (1992) Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Annal Neurol 31:551–554. https://doi.org/10.1002/ana.410310514 CrossRefPubMed

Mao X et al (2016) Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. https://doi.org/10.1126/science.aah3374 CrossRefPubMedPubMedCentral

Marcellino D et al (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283:26016–26025. https://doi.org/10.1074/jbc.M710349200 CrossRefPubMedPubMedCentral

Marcellino D, Lindqvist E, Schneider M, Muller CE, Fuxe K, Olson L, Galter D (2010) Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Disease 40:460–466. https://doi.org/10.1016/j.nbd.2010.07.008 CrossRef

Marshall FH, White J, Main M, Green A, Wise A (1999) GABA(B) receptors function as heterodimers. Biochem Soc Trans 27:530–535CrossRefPubMed

Milligan G (2013) The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol 84:158–169. https://doi.org/10.1124/mol.113.084780 CrossRefPubMedPubMedCentral

Millon C et al (2016) Galanin (1–15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system. Brain Struct Funct 221:4491–4504. https://doi.org/10.1007/s00429-015-1180-y CrossRefPubMed

Navarro G et al (2009) Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors. J Biol Chem 284:28058–28068. https://doi.org/10.1074/jbc.M109.034231 CrossRefPubMedPubMedCentral

Navarro G et al (2014) Intracellular calcium levels determine differential modulation of allosteric interactions within G protein-coupled receptor heteromers. Chem Biol 21:1546–1556. https://doi.org/10.1016/j.chembiol.2014.10.004 CrossRefPubMed

Navarro G, Borroto-Escuela DO, Fuxe K, Franco R (2016) Purinergic signaling in Parkinson’s disease. Relevan Treat Neuropharmacol 104:161–168. https://doi.org/10.1016/j.neuropharm.2015.07.024 CrossRef

Ogren SO (1985) Central serotonin neurones in avoidance learning: interactions with noradrenaline and dopamine neurones pharmacology. Biochem Behav 23:107–123CrossRef

Oueslati A (2016) Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? J Parkinson’s Disease 6:39–51. https://doi.org/10.3233/JPD-160779 CrossRef

Owen DM, Magenau A, Williamson DJ, Gaus K (2013) Super-resolution imaging by localization microscopy. Methods Mol Biol 950:81–93PubMed

Popoli P, Gimenez-Llort L, Pezzola A, Reggio R, Martinez E, Fuxe K, Ferre S (1996) Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neurosci Lett 218:209–213CrossRefPubMed

Popoli P et al (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors Neuropsychopharmacology: official publication of the American College. Neuropsychopharmacology 25:505–513. https://doi.org/10.1016/S0893-133X(01)00256-1 CrossRefPubMed

Rascol O et al (2001) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58:249–254CrossRefPubMed

Rebola N, Lujan R, Cunha RA, Mulle C (2008) Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 57:121–134. https://doi.org/10.1016/j.neuron.2007.11.023 CrossRefPubMed

Rimondini R, Ferre S, Gimenez-Llort L, Ogren SO, Fuxe K (1998) Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 347:153–158CrossRefPubMed

Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R (2002) Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 80:219–229CrossRefPubMed

Rivera A et al (2017) Dopamine D4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction. Addict Biol 22:1232–1245. https://doi.org/10.1111/adb.12407 CrossRefPubMed

Sauer R, Maurinsh J, Reith U, Fulle F, Klotz KN, Muller CE (2000) Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem 43:440–448CrossRefPubMed

Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson’s disease trends. Neurosciences 29:647–654. https://doi.org/10.1016/j.tins.2006.09.004 CrossRef

Shadfar S et al (2018) Neuroprotective effects of antidepressants via upregulation of neurotrophic factors in the MPTP model of Parkinson’s disease. Mol Neurobiol 55:554–566. https://doi.org/10.1007/s12035-016-0342-0 CrossRefPubMed

Shen W, Flajolet M, Greengard P, Surmeier DJ (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321:848–851. https://doi.org/10.1126/science.1160575 CrossRefPubMedPubMedCentral

Shumilov K, Real MA, Valderrama-Carvajal A, Rivera A (2018) Selective ablation of striatal striosomes produces the deregulation of dopamine nigrostriatal pathway. PloS One 13:e0203135. https://doi.org/10.1371/journal.pone.0203135 CrossRefPubMedPubMedCentral

Simons M, Raposo G (2009) Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol 21:575–581. https://doi.org/10.1016/j.ceb.2009.03.007 CrossRefPubMed

Stromberg I, Popoli P, Muller CE, Ferre S, Fuxe K (2000) Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 12:4033–4037CrossRefPubMed

Surmeier DJ, Graves SM, Shen W (2014) Dopaminergic modulation of striatal networks in health and Parkinson’s disease. Curr Opin Cell Biol 29:109–117. https://doi.org/10.1016/j.conb.2014.07.008 CrossRef

Surmeier DJ, Obeso JA, Halliday GM (2017a) Parkinson’s disease is not simply a prion disorder. J Neurosci 37:9799–9807. https://doi.org/10.1523/JNEUROSCI.1787-16.2017 CrossRefPubMedPubMedCentral

Surmeier DJ, Obeso JA, Halliday GM (2017b) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18:101–113. https://doi.org/10.1038/nrn.2016.178 CrossRefPubMedPubMedCentral

Tanganelli S et al (2004) Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson’s Disease. Parkinsonism Relat Disord 10:273–280. https://doi.org/10.1016/j.parkreldis.2004.02.015 CrossRefPubMed

Tarakanov AO, Fuxe KG (2010) Triplet puzzle: homologies of receptor heteromers. J Mol Neurosci 41:294–303. https://doi.org/10.1007/s12031-009-9313-5 CrossRefPubMed

Tarakanov AO, Fuxe KG, Borroto-Escuela DO (2011) On the origin of the triplet puzzle of homologies in receptor heteromers: immunoglobulin triplets in different types of receptors. J Mol Neurosci 46:616–621. https://doi.org/10.1007/s12031-011-9649-5 CrossRefPubMed

Tarakanov AO, Fuxe KG, Borroto-Escuela DO (2012) Integrin triplets of marine sponges in human brain receptor heteromers. J Mol Neurosci 48:154–160. https://doi.org/10.1007/s12031-012-9793-6 CrossRefPubMed

Torvinen M, Marcellino D, Canals M, Agnati LF, Lluis C, Franco R, Fuxe K (2005) Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67:400–407 https://doi.org/10.1124/mol.104.003376 CrossRefPubMed

Trifilieff P et al (2011) Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Bio Tech 51:111–118 https://doi.org/10.2144/000113719 CrossRef

Ward RJ, Pediani JD, Godin AG, Milligan G (2015) Regulation of oligomeric organization of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor observed by spatial intensity distribution analysis. J Biol Chem 290:12844–12857. https://doi.org/10.1074/jbc.M115.644724 CrossRefPubMedPubMedCentral

Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74:858–873. https://doi.org/10.1016/j.neuron.2012.03.017 CrossRefPubMed

Woods AS, Ciruela F, Fuxe K, Agnati LF, Lluis C, Franco R, Ferre S (2005) Role of electrostatic interaction in receptor–receptor heteromerization. J Mol Neurosci 26:125–132. https://doi.org/10.1385/JMN:26:2-3:125 CrossRefPubMed

Title: Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment
Authors: Dasiel O. Borroto-Escuela
Kjell Fuxe
Publication date: 01-04-2019
Publisher: Springer Vienna
Keywords: Parkinson's Disease
Levodopa
Published in: Journal of Neural Transmission / Issue 4/2019
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-01969-2

At a glance: The STEP trials

Springer Medicine

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder

Classical dopamine agonists

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

Dopaminergic modulation of striatal function and Parkinson’s disease

Is Braak staging valid for all types of Parkinson’s disease?